Study of Antidepressants in Parkinson's Disease (SAD-PD)
3 de enero de 2013 actualizado por: Irene Richard, University of Rochester
The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Nearly 50 percent of individuals with Parkinson's disease (PD) suffer from depression-a condition that causes disability and can reduce quality of life. The University of Rochester Medical Center is conducting a research study of antidepressant medications to find out more about how to treat depression in PD. Antidepressant medications have not been adequately studied in persons with PD.
The purpose of this study is to find out if the antidepressant medications paroxetine and venlafaxine can help control depression in PD and whether or not these medications affect the motor symptoms of PD such as tremor, stiffness, slowness, and balance.
This is a randomized, double blind, placebo-controlled, 12-week study of paroxetine immediate release (Paxil) and venlafaxine extended release (Effexor XR). Paroxetine and venlafaxine XR are drugs that have been approved by the Food and Drug Administration (FDA) and are available by prescription. Paroxetine and venlafaxine XR have been shown to be effective in treating depression in the general population. Two hundred, twenty-eight persons will be enrolled among 15 medical centers throughout the United States and Canada. Each person will participate in the trial for 12 weeks. Each participant will be randomly assigned to take either paroxetine or venlafaxine, or a placebo.
Tipo de estudio
Intervencionista
Inscripción (Actual)
115
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Ontario
-
London, Ontario, Canadá, N6A 5A5
- London Health Sciences Centre, University Campus Room A10-325, 339 Windermere Road
-
-
Quebec
-
Montreal, Quebec, Canadá, H2W 1T8
- Hotel-Dieu Hospital-CHUM
-
-
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- University of Florida
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University School of Medicine
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21218
- Johns Hopkins University
-
Baltimore, Maryland, Estados Unidos, 21250
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center, Dept. of Neurology E/KS 430, 330 Brookline Avenue
-
-
Missouri
-
St. Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
New York
-
Rochester, New York, Estados Unidos, 14627
- University of Rochester
-
-
Ohio
-
Toledo, Ohio, Estados Unidos
- Medical University of Ohio
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health Sciences University
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38163
- University of Tennessee-Memphis
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine, 6550 Fannin, Suite 1801
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22901
- University of Virginia
-
-
-
-
-
San Juan, Puerto Rico, 00936
- University of Puerto Rico
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
30 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
To be eligible you must be:
- 30 years old or older
- diagnosed with Parkinson's disease
- experiencing symptoms of depression such as sadness, decreased energy, or problems sleeping
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: paroxetine
Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
|
Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks.
If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated).
Dosage for this study will not exceed 40 mg.
Otros nombres:
|
|
Comparador activo: venlafaxine extended release
Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
|
Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks.
If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated).
Dosage for this study will not exceed 225 mg.
Otros nombres:
|
|
Comparador de placebos: placebo
Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
|
una sustancia inactiva
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Hamilton Depression Rating Scale (HAM-D) Scores
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Change in Hamilton Rating Scale for Depression over 12 weeks.
Hamilton Depression Rating Scale ranges from 0-50.
Higher scores represent more significant depression.
Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Montgomery-Asberg Depression Rating Scale (MADRS)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Montgomery-Asberg Depression Rating Scale ranges from 0-60.
Higher score indicates more severe depression.
0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Beck Depression Inventory II (BDI-II)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Beck Depression Inventory II ranges from 0-63.
Higher score indicates more severe depression.
0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Geriatric Depression Rating Scale (GDS)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Geriatric Depression Scale ranges from 0-30.
Higher score indicates more severe depression.
0-9 normal, 10-19 mild depression, 20-30 severe depression.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Brief Psychiatric Rating Scale (BPRS)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Brief Psychiatric Rating Scale.
Maximum score 126.
Higher score indicates greater psychiatric difficulties.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Unified Parkinson's Disease Rating Scale (UPDRS)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Unified Parkinson's Disease Rating Scale.
Higher score indicates more severe Parkinson's disease symptoms.
Total maximum = 176.
Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72.
Minimum = 0.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Snaith Clinical Anxiety Scale (CAS)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Snaith Clinical Anxiety Scale.
Range 0-21.
Higher scores indicate increased anxiety.
Score greater than 8 indicates clinical anxiety.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23.
Higher score indicates more severe Parkinson's disease symptoms.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Parkinson's Disease Questionnaire (PDQ-39) Total.
Range 0-100.
Lower score indicates a better perceived health status.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Short Form 36 Health Survey - Mental Component Summary
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Short Form 36 Health Survey.
Range 0-100.
Higher score indicates a better perceived quality of life.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Short Form 36 Health Survey - Vitality
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Short Form 36 Health Survey - Vitality subscale ranges from 0-100.
Higher score indicates a better perceived quality of life.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Short Form 36 Health Survey - Role-Emotional
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Short Form 36 Health Survey - Emotional subscale ranges from 0-100.
Higher score indicates a better perceived quality of life.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
|
Change in Short Form 36 Health Survey - Mental Health
Periodo de tiempo: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100.
Higher score indicates a better perceived quality of life.
|
from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Irene Richard, MD, University of Rochester
- Investigador principal: William McDonald, MD, Co-Principal Investigator--Emory University School of Medicine
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
- HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
- Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49. doi: 10.1016/0022-3956(82)90033-4.
- Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93-113. doi: 10.1016/0197-2456(81)90001-5.
- Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97. doi: 10.1207/s15327752jpa6703_13.
- Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC. The correlation of depression with functional activity in Parkinson's disease. J Neurol. 1997 Aug;244(8):493-8. doi: 10.1007/s004150050131.
- Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001 Nov;62(11):869-77. doi: 10.4088/jcp.v62n1106.
- Global Parkinson's Disease Survey (GPDS) Steering Committee.. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002 Jan;17(1):60-7. doi: 10.1002/mds.10010.
- Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol. 1992 Mar;49(3):305-7. doi: 10.1001/archneur.1992.00530270125028.
- Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord. 2000 Mar;15(2):216-23. doi: 10.1002/1531-8257(200003)15:23.0.co;2-#.
- Phillips P. Keeping depression at bay helps patients with Parkinson disease. JAMA. 1999 Sep 22-29;282(12):1118-9. No abstract available.
- Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009 Mar 10;72(10):886-92. doi: 10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.
- Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destee A, Bordet R, Defebvre L. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008 Apr 30;23(6):850-7. doi: 10.1002/mds.21966.
- Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46(3):125-35. doi: 10.1159/000066390.
- Yeragani VK, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002 Sep 1;52(5):418-29. doi: 10.1016/s0006-3223(02)01394-x.
- Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS, Robin DW, Gergel I, McCafferty J, Roose S. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999 Jul;156(7):1024-8. doi: 10.1176/ajp.156.7.1024.
- Simons JA. Fluoxetine in Parkinson's disease. Mov Disord. 1996 Sep;11(5):581-2. doi: 10.1002/mds.870110517. No abstract available.
- Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology. 1993 Jan;43(1):211-3. doi: 10.1212/wnl.43.1_part_1.211.
- Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology. 1994 Dec;44(12):2406. doi: 10.1212/wnl.44.12.2406. No abstract available.
- Salzman C. Pharmacologic treatment of depression in the elderly. J Clin Psychiatry. 1993 Feb;54 Suppl:23-8.
- Altamura AC, De Novellis F, Guercetti G, Invernizzi G, Percudani M, Montgomery SA. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res. 1989;9(6):391-6.
- Feighner JP, Boyer WF, Meredith CH, Hendrickson G. An overview of fluoxetine in geriatric depression. Br J Psychiatry Suppl. 1988 Sep;(3):105-8. No abstract available.
- Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990 Dec;51 Suppl B:28-33.
- Dubovsky S. Geriatric Neuropsychopharmacology. In: Coffey C, Cummings J, eds. Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press, 1994:595-631.
- Dunner DL, Cohn JB, Walshe T 3rd, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC Jr, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992 Feb;53 Suppl:57-60.
- Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl. 1989;350:132-4. doi: 10.1111/j.1600-0447.1989.tb07192.x. No abstract available.
- Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999 May;60(5):326-35. doi: 10.4088/jcp.v60n0511.
- Gentil V, Kerr-Correa F, Moreno R, D'Arrigo Busnello E, De Campos JA, Juruena MF, Lafer B, Moreno DH, De Cassia Rodrigues RL, Tiosso A, Benedictis E. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol. 2000 Mar;14(1):61-6. doi: 10.1177/026988110001400108.
- Applebaum PS, Grisso T. MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research. Sarasota, FL: Professional Resource Press, 2001.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, 1994.
- Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for Axis I DSM-IV disorders: Biometrics Research Department. New York State Psychiatric Institute 1994.
- Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull. 1985;21(4):809-43. No abstract available.
- Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information, 1992:153-163.
- Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC; Parkinson Study Group DATATOP Investigators. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009 Nov 3;73(18):1469-77. doi: 10.1212/WNL.0b013e3181bf992f.
- Little RJA, Rubin DB. Statistical Analysis with Missing Data, Second Edition. Hoboken: John Wiley and Sons, 2002.
- McDonald WM, Holtzheimer PE, Haber M, Vitek JL, McWhorter K, Delong M. Validity of the 30-item geriatric depression scale in patients with Parkinson's disease. Mov Disord. 2006 Oct;21(10):1618-22. doi: 10.1002/mds.21023.
- Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology. 2009 Mar 10;72(10):868-9. doi: 10.1212/01.wnl.0000338145.24512.02. Epub 2008 Dec 17. No abstract available.
- Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One. 2009;4(3):e4824. doi: 10.1371/journal.pone.0004824. Epub 2009 Mar 18.
- Senn S, Julious S. Measurement in clinical trials: a neglected issue for statisticians? Stat Med. 2009 Nov 20;28(26):3189-209. doi: 10.1002/sim.3603.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de junio de 2005
Finalización primaria (Actual)
1 de noviembre de 2009
Finalización del estudio (Actual)
1 de noviembre de 2009
Fechas de registro del estudio
Enviado por primera vez
28 de junio de 2004
Primero enviado que cumplió con los criterios de control de calidad
28 de junio de 2004
Publicado por primera vez (Estimar)
29 de junio de 2004
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
4 de enero de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
3 de enero de 2013
Última verificación
1 de enero de 2013
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Síntomas de comportamiento
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Trastornos Parkinsonianos
- Enfermedades de los ganglios basales
- Trastornos del movimiento
- Sinucleinopatías
- Enfermedades neurodegenerativas
- Depresión
- Enfermedad de Parkinson
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Drogas psicotropicas
- Inhibidores de la captación de serotonina
- Inhibidores de la captación de neurotransmisores
- Moduladores de transporte de membrana
- Agentes de serotonina
- Agentes antidepresivos
- Inhibidores de enzimas del citocromo P-450
- Agentes antidepresivos, segunda generación
- Inhibidores de la recaptación de serotonina y noradrenalina
- Inhibidores del citocromo P-450 CYP2D6
- Paroxetina
- Clorhidrato de venlafaxina
Otros números de identificación del estudio
- R01NS046487 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .